Sitemap > Breaking Research > Infectious Diseases
Displaying 401 - 450 of 4290 results
- Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
- Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
- Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
- Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge.
- HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
- Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
- Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
- Histatin and lactoferrin derived peptides: antimicrobial properties and effects on mammalian cells.
- Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.
- Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.
- Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
- Drug-induced regulation of the MDR1 promoter in Candida albicans.
- Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
- Imipenem for treatment of tuberculosis in mice and humans.
- Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
- Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.
- Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus.
- In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
- Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
- In vitro and in vivo bactericidal activities of vancomycin dispersed in porous biodegradable poly(epsilon-caprolactone) microparticles.
- In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.
- In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
- Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.
- Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. II. Structure elucidation.
- Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
- Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART.
- Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis.
- Interaction of silver nanoparticles with HIV-1.
- Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
- Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
- Harmful and protective roles of neutrophils in sepsis.
- Rapid alterations in transferrin sialylation during sepsis.
- Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation.
- Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: Chemical derivatization.
- Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
- Synthesis and antibacterial activity of alkyl derivatives of the glycopeptide antibiotic A40926 and their amides.
- Novel 3-amino-2-hydroxy acids containing protease inhibitors. Part 1: Synthesis and kinetic characterization as aminopeptidase P inhibitors.
- Structure-based design, synthesis, and in vitro assay of novel nucleoside analog inhibitors against HIV-1 reverse transcriptase.
- Antiviral cyclic D,L-alpha-peptides: targeting a general biochemical pathway in virus infections.
- 9-Oxime-3-ketolides: modification at the C-11,12-diol moiety and antibacterial activities against key respiratory pathogens.
- Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.
- Identification of a universal Group B streptococcus vaccine by multiple genome screen.
- Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
- Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication.
- Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication.
- A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.
- Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.
- Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis.
- Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
- In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >